Study Finds Drug Combination may Reduce Suicide Risk Faster

Modern psychiatry has long struggled with one brutal reality: people at the highest risk of suicide often cannot wait weeks for therapy or antidepressants to take effect.

Roughly 13 million Americans seriously consider suicide each year and about 50,000 deaths annually.

Now, a new study suggests researchers may have identified a drug regimen capable of delivering rapid and sustained relief from suicidal thoughts across a broad group of patients, Ariana Eunjung Cha reported for The Washington Post.

Suicide remains one of the United States’ most pressing public health crises, with roughly 13 million Americans seriously considering suicide each year and about 50,000 deaths annually.

A study scheduled to be presented Tuesday at the annual meeting of the American Psychiatric Association found that a combination of treatments — a single ketamine infusion followed by low-dose Buprenorphine — sustained reductions in suicidal ideation among adults with major depressive disorder.

“This is really a breakthrough study that provides hope and immediate clinical applications,” said Ned Kalin, editor-in-chief of the journal set to publish the paper and chair of psychiatry at the University of Wisconsin School of Medicine and Public Health.

However, outside experts urged caution.

Bertha Madras, a professor of psychobiology at Harvard Medical School, said promising short-term treatments often reveal risks only after broader and longer-term use.

Similarly, Carl Hart warned against overstating the results, noting that while the study showed improvement in suicidal thoughts, it did not demonstrate differences in depressive symptoms between participants receiving the drug combination and those given a placebo.